Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This text provides contact information and no new research findings are reported.

This article reviews the limited evidence on testosterone therapy for premenopausal women and notes a lack of long-term safety and effectiveness data for this population.

This review discusses the regulation of hair growth, causes of excessive androgen secretion, and current safe solutions for hyperandrogenism manifestations in women but reports no new clinical results.

This study highlights the severe health risks and dependence associated with non-medical androgen use among gym-goers, stressing the need for specialized primary care and harm-reduction strategies due to potentially fatal outcomes even after prolonged cessation.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

This review discusses various treatment options for androgenic alopecia, noting finasteride's greater efficacy in men and identifies ongoing research needs, particularly for therapies like laser and stem cells.

This review outlines the major health consequences of anabolic-androgenic steroid abuse, with a focus on sexual and reproductive issues, and suggests management prioritizes cessation and relapse prevention due to lack of robust randomized trials.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

The document concludes that there are various causes and treatments for hair loss, with hair transplantation being a notable option.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

This study concluded that dutasteride 0.5 mg/day improved hair growth in patients with androgenetic alopecia over six months but was associated with a higher prevalence of sexual dysfunction.

This review discusses post-finasteride syndrome, highlighting occasional adverse sexual and systemic effects in men and women, but reports no new research findings while emphasizing the need for better education about the drug's risks.

The conclusion is that different types of hair loss in dogs and cats can be cosmetic or serious, and affected animals should not be bred.

This case report emphasizes the importance of investigating physical symptoms in patients with depression, as persistent loss of libido in this patient led to the diagnosis of craniopharyngioma.

Finasteride caused serious side effects and led to six suicides.

Finasteride for female hair loss has low side effects, more research needed.

This literature review reports prevalent sexual dysfunctions, notably vaginal dryness, in women undergoing endocrine therapy for hormone-dependent breast cancer, highlighting the need for more multidisciplinary research and care to improve patient well-being.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This study found that finasteride significantly improved symptoms in CP/CPPS patients, except for voiding, unlike saw palmetto which showed no long-term benefits.

This review examines androgen replacement therapy in women for treating androgen deficiency symptoms and reports no new clinical results, while noting potential safety within a specific dose range.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This study observed that most hirsute patients on combined cyproterone acetate and 'Diane' therapy experienced a reduction in hair growth, with hair becoming softer, thinner, and lighter in color over 12 months.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This review discusses the pharmacology and safety of topical finasteride for treating androgenetic alopecia and female pattern hair loss, noting positive results but reporting no new clinical findings.

This review suggests that while finasteride for male pattern hair loss was previously considered safe, there is now evidence associating 5-α reductase inhibitors with significant sexual and reproductive side effects.